Menu

Lupin Receives Tentative Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets

July 16, 2024

Mumbai, Naples, July 16, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, 1.479 g/0.225 g/0.188 g, to market a generic equivalent of Sutab® Tablets, 1.479 g/0.225 g/0.188 g, of Braintree Laboratories Inc. Lupin is the exclusive first-to-file for this product and may be eligible to receive a 180-day exclusivity . This product will be manufactured at Lupin’s Nagpur facility in India.

Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults.

Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets (RLD Sutab®) had an estimated annual sale of USD148million in the U.S. (IQVIA MAT May 2024).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.8% of its revenue in research and development in FY24.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

For further information or queries please contact –

Heena Dhedhi

Deputy General Manager – Corporate Communications

heenadhedhi@lupin.com

*Safe Harbor Statement

Sutab® is a registered trademark of Braintree Laboratories Inc.

Related Post
Smart Guide
Consent to Collection CookieTest

This website uses cookies to enhance your overall web browsing experience, provide you with ads tailored to your interests, and allow us to measure our audience and collect other analytical data about the use of our website.

By clicking "Accept All" you consent to the collection of your personal information (which may include your Consumer Health Data) through 1st and 3rd party cookies (or similar). To edit your cookie preferences, use the options below.

For more information, please visit our Privacy Statement.

Depending on where you live, you may also be able to exercise your right to opt out or withdraw your consent.Do Not Sell/Share My Personal Information.